Ferric carboxymaltose meets primary goal of anemia treatment study

07/12/2013 | PharmaTimes (U.K.)

Ferinject, or intravenous ferric carboxymaltose, met the main goal of a clinical trial by significantly reducing the use of erythropoiesis-stimulating agents and transfusions among patients with non-dialysis-dependent chronic kidney disease. More than 600 patients participated in the international, 56-week study. They received either oral iron or 1,000 milligrams of ferric carboxymaltose initially and more as needed.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC